Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
暂无分享,去创建一个
Lee Bowman | Joseph A Johnston | D. Feeny | L. Matza | J. Johnston | K. Boye | J. Jordan | L. Bowman | David H Feeny | Kristina S Boye | Louis S Matza | Jessica B Jordan
[1] G W Torrance,et al. Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials: Two Examples , 1989, Medical care.
[2] N. Ikegami,et al. Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.
[3] E. Verrips,et al. Health-Related Quality of Life for Extremely Low Birth Weight Adolescents in Canada, Germany, and the Netherlands , 2008, Pediatrics.
[4] M. Trommald,et al. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method , 2004, Journal of health services research & policy.
[5] M. Palta,et al. Agreement about Identifying Patients Who Change over Time , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] H. Kohli. Scottish Medicines Consortium. , 2005, The National medical journal of India.
[7] Katherine Stevens,et al. Developing a descriptive system for a new preference-based measure of health-related quality of life for children , 2009, Quality of Life Research.
[8] N. Payakachat,et al. Measuring health and well-being effects in family caregivers of children with craniofacial malformations , 2011, Quality of Life Research.
[9] S. Gupta,et al. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD , 2004, Ophthalmic epidemiology.
[10] J. Salomon,et al. Preferences for health outcomes associated with Group A Streptococcal disease and vaccination , 2010, Health and quality of life outcomes.
[11] L. Matza,et al. Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] J. Levin,et al. Racial/ethnic differences in preferences for the EQ-5D health states: results from the U.S. valuation study. , 2007, Journal of clinical epidemiology.
[13] A. Haiderali,et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia , 2013, The European Journal of Health Economics.
[14] D. Feeny. Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[15] P. Dolan,et al. To what extent can we explain time trade-off values from other information about respondents? , 2002, Social science & medicine.
[16] P. Mohr,et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores , 2004, Schizophrenia Research.
[17] A. G. Witney,et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. , 2006, Rheumatology.
[18] Tsuguya Fukui,et al. Utilities Measured by Rating Scale, Time Trade-off, and Standard Gamble: Review and Reference for Health Care Professionals , 2002, Journal of epidemiology.
[19] D. Revicki,et al. Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis , 2013, Quality of Life Research.
[20] J. Brazier,et al. Health Utility Measurement , 2011 .
[21] G. Torrance. Utility measurement in healthcare: the things I never got to. , 2006, PharmacoEconomics.
[22] Elaine L. Zanutto,et al. A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes , 2010, Journal of medical economics.
[23] R. Keren,et al. Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children , 2012, PharmacoEconomics.
[24] J. Pater. Quality of life and pharmacoeconomics in clinical trials , 1996 .
[25] D K Owens,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.
[26] J. Kenneth Buckingham,et al. Comparing Three Versions of the Time Tradeoff , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.
[27] S. Petrou,et al. Measurement of health utilities in children , 2009 .
[28] Aki Tsuchiya,et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.
[29] I. Béjia,et al. Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients , 2006, Clinical Rheumatology.
[30] S. Dursun,et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation , 2008, Health and quality of life outcomes.
[31] Lisa M. Schwartz,et al. Assessing Values for Health: Numeracy Matters , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] G. Bonsel,et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study , 2010, Quality of Life Research.
[33] M. Jofre-Bonet,et al. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma , 2012, BMC Ophthalmology.
[34] S. Dewilde,et al. Eliciting health state utilities from the general public for severe chronic pain , 2010, The European Journal of Health Economics.
[35] R. Edwards,et al. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] Michael Herdman,et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D , 2010, Quality of Life Research.
[37] J. Guest,et al. Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom , 2012, Leukemia & lymphoma.
[38] David O Meltzer,et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. , 2006, Diabetes care.
[39] J. Brazier,et al. Whose values in health? An empirical comparison of the application of adolescent and adult values for the CHU-9D and AQOL-6D in the Australian adolescent general population. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[40] R. Osborne,et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[41] J. Brazier,et al. Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. , 2006, Health economics.
[42] Kimberly N. Walter,et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes , 2011, The European Journal of Health Economics.
[43] R. Goeree,et al. A review of health utilities across conditions common in paediatric and adult populations , 2010, Health and quality of life outcomes.
[44] Peter C. Smith,et al. The Oxford Handbook of Health Economics , 2013 .
[45] N Mittmann,et al. Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Salomon,et al. Health and Quality of Life Outcomes Health-state Valuations for Pertussis: Methods for Valuing Short-term Health States Pertussistime Trade-offwillingness-to-payshort-term Health-state , 2022 .
[47] P. Cristoforoni,et al. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy. , 2011, Clinical therapeutics.
[48] C. Carswell. Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.
[49] Health state utilities for metastatic breast cancer , 2006, British Journal of Cancer.
[50] J. Brazier,et al. The Use of Rasch Analysis in Reducing a Large Condition-Specific Instrument for Preference Valuation , 2011, Medical decision making.
[51] A. Caughey,et al. A community-based study of acne-related health preferences in adolescents. , 2008, Archives of dermatology.
[52] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[53] E. Wittenberg. Valuing Children’s Health , 2012, PharmacoEconomics.
[54] A. Stiggelbout,et al. Evaluation of the Treatment Tradeoff Method in Rectal Cancer Patients: Is Surgery Preference Related to Outcome Utilities? , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[55] D A Revicki,et al. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.
[56] M. Versteegh,et al. Time trade-off: one methodology, different methods , 2013, The European Journal of Health Economics.
[57] Patrick M M Bossuyt,et al. A Comparison of 3 Valuation Methods for Temporary Health States in Patients Treated with Oral Anticoagulants , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[58] D. Feeny,et al. Health-Related Quality of Life in Survivors of Wilms’ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study , 2000 .
[59] Peter P. Wakker,et al. The Utility of Health States After Stroke: A Systematic Review of the Literature , 2001, Stroke.
[60] A. Zwinderman,et al. Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis , 2000, Annals of the rheumatic diseases.
[61] J. Schmitt,et al. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population‐based study , 2007, The British journal of dermatology.
[62] Mark L. Greenberg,et al. Health-related quality of life (HRQL) scores reported from parents and their children with chronic illness differed depending on utility elicitation method. , 2004, Journal of clinical epidemiology.
[63] P. Stalmeier,et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. , 2006, Health economics.
[64] W. Brouwer,et al. The influence of subjective life expectancy on health state valuations using a 10 year TTO. , 2009, Health economics.
[65] J. Brazier,et al. Valuing child health utility 9D health states with a young adolescent sample , 2011, Applied health economics and health policy.
[66] O. Norheim,et al. Quantifying quality of life for economic analysis: time out for time trade off , 2003, Medical humanities.
[67] Wendy J. Ungar,et al. Challenges in Health State Valuation in Paediatric Economic Evaluation , 2011, PharmacoEconomics.
[68] S. Kulasingam,et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. , 2009, Gynecologic oncology.
[69] B. O'brien,et al. Are health states "timeless"? The case of the standard gamble method. , 1999, Journal of clinical epidemiology.
[70] Dennis A. Revicki,et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report , 2003, Quality of Life Research.
[71] L. Matza,et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases , 2013, Patient preference and adherence.
[72] R. Sheldon,et al. Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens , 2012, PharmacoEconomics.
[73] Katherine Stevens,et al. Valuation of the Child Health Utility 9D Index , 2012, PharmacoEconomics.
[74] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[75] X. Badia,et al. Feasibility, validity and test–retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off , 1999, Quality of Life Research.
[76] Sarah A. Edwards,et al. Characteristics and quality of pediatric cost-utility analyses , 2012, Quality of Life Research.
[77] I. Kaitila,et al. Quality of life in pre-adolescence: A 17-dimensional health-related measure (17D) , 1996, Quality of Life Research.
[78] L. Matza,et al. Utilities and disutilities for type 2 diabetes treatment-related attributes , 2007, Quality of Life Research.
[79] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[80] M. Barrera,et al. Health Status in Survivors of Cancer in Childhood and Adolescence , 2006, Quality of Life Research.
[81] K. McPherson,et al. Measuring the impact of menopausal symptoms on quality of life. , 1993, BMJ.
[82] M. Trommald,et al. Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies. , 2005, Health economics.
[83] Wendy J. Ungar,et al. Economic Evaluation in Child Health , 2010 .
[84] S. Alibhai,et al. Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients , 2012, Supportive Care in Cancer.
[85] I. Kaitila,et al. Quality of life in early adolescence: A sixteendimensional health-related measure (16D) , 1996, Quality of Life Research.
[86] D. Feeny,et al. A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] A. Stiggelbout,et al. Correcting Biases in Standard Gamble and Time Tradeoff Utilities , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[88] M. Buxton,et al. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? , 1994, Quality of Life Research.
[89] Jackie Brown,et al. Valuing temporary and chronic health states associated with breast screening. , 1998, Social science & medicine.
[90] A. Culyer. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE , 1958 .
[91] Katherine Stevens,et al. Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation , 2011, Applied health economics and health policy.
[92] M. Barkham,et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). , 2012, Health technology assessment.
[93] D. Feeny,et al. The Health Utilities Index (HUI®): concepts, measurement properties and applications , 2003, Health and quality of life outcomes.
[94] D. Meltzer,et al. Health Utilities for Children and Adults With Type 1 Diabetes , 2011, Medical care.
[95] N. Bressler,et al. Rasch analysis in the development of a simplified version of the national eye institute visual-function questionnaire-25 for utility estimation , 2012, Quality of Life Research.
[96] C Browne,et al. Estimating quality-adjusted life years from patient-reported visual functioning , 2012, Eye.
[97] P. Dolan,et al. Valuing health status using VAS and TTO: what lies behind the numbers? , 1997, Social science & medicine.
[98] Jonathan C Tosh,et al. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[99] M. Angermeyer,et al. Utility Assessment in Patients with Mental Disorders , 2012, PharmacoEconomics.
[100] Nan Luo,et al. Valuations of EQ-5D Health States: Are the United States and United Kingdom Different? , 2005, Medical care.
[101] J. Brazier,et al. Outcomes of social care for adults: developing a preference-weighted measure. , 2012, Health technology assessment.
[102] L. Matza,et al. Health state utilities for skeletal-related events secondary to bone metastases , 2013, The European Journal of Health Economics.
[103] B. O'brien,et al. Holistic versus Composite Preferences for Lifetime Treatment Sequences for Type 2 Diabetes , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[104] J. Brazier,et al. Developing preference-based health measures: using Rasch analysis to generate health state values , 2010, Quality of Life Research.
[105] B. Spilker,et al. Quality of life and pharmacoeconomics in clinical trials , 1996 .
[106] D. Wild,et al. Reimbursement agency requirements for health related quality-of-life data: a case study , 2009, Expert review of pharmacoeconomics & outcomes research.
[107] R. Hornung,et al. Health values of patients with systemic sclerosis. , 2007, Arthritis and rheumatism.
[108] P. Dolan,et al. The time trade-off method: results from a general population study. , 1996, Health economics.
[109] M. Kuppermann,et al. Can Preference Scores for Discrete States Be Used to Derive Preference Scores for an Entire Path of Events? , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[110] Alan Shiell,et al. Extrinsic Goals and Time Tradeoff , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[111] A. Leonard,et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS , 2006, Journal of General Internal Medicine.
[112] Martin Knapp,et al. The Oxford Handbook of Health Economics , 2011 .
[113] Peter P. Wakker,et al. A Study of the Chained Procedure for the Standard Gamble and Time Tradeoff , 2008 .
[114] M. Yi,et al. Health values in adolescents with or without inflammatory bowel disease. , 2009, The Journal of pediatrics.
[115] J. Brazier,et al. Preference-based condition-specific measures of health: what happens to cross programme comparability? , 2010, Health economics.
[116] Andrew Dalton,et al. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study , 2012, Health and Quality of Life Outcomes.
[117] L. Prosser,et al. Methods for Measuring Temporary Health States for Cost-Utility Analyses , 2012, PharmacoEconomics.
[118] S. Saw,et al. Utility assessment among cataract surgery patients , 2005, Journal of cataract and refractive surgery.